Cited by 10Multiple Sclerosis Research StudiesCancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

The four self-efficacy trajectories among people with multiple sclerosis: clinical associations and implications

Young, Carolyn A., Mills, Roger, Langdon, Dawn, Sharrack, Basil, Majeed, Tahir, Kalra, Seema, Footitt, David, Rog, David +11 more·2022·Journal of the Neurological Sciences

Abstract

Background Longitudinal studies among people with Multiple Sclerosis (pwMS) have shown that self-efficacy is linked to physical, cognitive and psychological functioning.Objectives To determine the distribution of self-efficacy in a large sample of pwMS, examining whether there are distinct groups which show different self-efficacy trajectories over time, and the health status characteristics of any groups identified.Methods Participants completed serial questionnaire packs, including Unidimensional Self-efficacy-MS (USE-MS) scale, for the Trajectories of Outcome in Neurological Conditions-MS (TONiC-MS) study over an average 46-month period. The resulting longitudinal data were analysed by a group-based trajectory model.Results 5887 pwMS were studied: mean age 50.2 years (SD 12.0); 73.6% female; Relapsing Remitting MS (61.8%), Secondary Progressive (22.9%), Primary Progressive (11.1%), Rapidly Evolving Relapsing Remitting MS (4.2%). Four distinct self-efficacy trajectories emerged, with declining, slightly declining, stable or improving self-efficacy, each showing different patterns of health status indicators such as EQ-5D-5L, disability and depression. USE-MS ≤ 18 at baseline detected all participants in the two declining groups.Conclusion Future trials on interventions for self-efficacy should assume a priori that those with low levels of self-efficacy (USE-MS ≤ 18 at baseline) are likely to be on a declining trajectory and may need different interventions from those with stable self-efficacy.

Integrity signals

Registry

Crossref · 10.1016/j.jns.2022.120188

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Young, C. A., Mills, R., Langdon, D., Sharrack, B., Majeed, T., Kalra, S., Footitt, D., Rog, D., Harrower, T., Nicholas, R., Woolmore, J., Thorpe, J., Hanemann, C. O., Ford, H., Paling, D., Ellis, C., Palace, J., Constantinescu, C., & Tennant, A.
Affiliations
  • University of Liverpool (GB)
  • Royal Holloway University of London (GB)
  • NIHR Sheffield Biomedical Research Centre (GB)
  • Lancashire Teaching Hospitals NHS Foundation Trust (GB)
  • University Hospitals of North Midlands NHS Trust (GB)
  • North Cumbria Integrated Care NHS Foundation Trust (GB)
  • Salford Royal NHS Foundation Trust (GB)
  • Imperial College Healthcare NHS Trust (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • Peninsula College of Medicine and Dentistry (GB)
  • Leeds Teaching Hospitals NHS Trust (GB)
  • Darent Valley Hospital (GB)
  • University of Nottingham (GB)
  • University of Leeds (GB)
Corresponding author
Young, Carolyn A.
Venue
Journal of the Neurological Sciences
Publisher
Elsevier BV
Published
2022-05
Volume
436
Pages
120188
ISSN
0022-510X (ISSN-L)
OpenAlex
W4213235386
Cited by
10
References
45
Citations by year
2026: 5 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2
FWCI
0.85
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the Neurological Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Teva Pharmaceutical Industries
  • Novartis
  • Sanofi Genzyme
  • Roche
  • Multiple Sclerosis Society (62)
  • Merck
  • Biogen
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
multiple sclerosis, self-efficacy, group-based trajectory modeling, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, disability, depression, health-related quality of life, EQ-5D-5L
MeSH terms
Female, Humans, Longitudinal Studies, Male, Middle Aged, Multiple Sclerosis, Surveys and Questionnaires, Self Efficacy, Multiple Sclerosis, Relapsing-Remitting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review